Osteoporosis with or without prior pathological fracture, mostly in postmenopausal women
Conditions
Interventions
Group 1: drug therapy using romosozumab
Group 2: drug therapy using teriparatide
Sponsors
Klinikum der LMU München; MUM; Klinik für Orthopädie und Unfallchirurgie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Patient at the LMU Munich Clinic with a diagnosis of osteoporosis Specific osteoporosis therapy with Romosozumab (trade name: Evenity) or - Teriparatide (trade name: Forsteo) - Bone density measurement before the start and after the end of therapy - Bone density measurement up to 6 months before the start of therapy and up to 6 months after the end of therapy - Bone density measurement using the same method - Bone density measurement before and after therapy on the same device
Exclusion criteria
Exclusion criteria: - Missing bone density measurement before or after therapy - Bone density measurement conducted more than 6 months before the start of therapy or more than 6 months after the end of therapy - Inadequate execution of the therapy, meaning Evenity for less than 12 months and Forsteo for less than 24 months, or taken with interruptions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| increase of bone density before vs after the therapy for both pills | — |
Secondary
| Measure | Time frame |
|---|---|
| Increase of bone density after the therapy, taking the prior medication into account. Therefore we compare treatment-naive patients with pre-treated patients and evaluate the difference of romosozumab or teriparatide on those two groups. | — |
Countries
Germany
Contacts
Public ContactIsa Feist-Pagenstert
Klinikum der LMU München; MUM; Klinik für Orthopädie und Unfallchirurgie
Outcome results
None listed